Hansa Biopharma AB (publ)

kr 39.46As of Sun 8 Nov 2026, 12:00 UTC
STO:HNSAHealthcare
Country Sweden
PE (Fwd) •••
TSR 10Y CAGR (6.02%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 1.68
PE TTM —
TSR TTM 26.47%
Mkt cap kr 4.016B
ROIC (73.76%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 41
3.94%
(82.51%)
Hold 2|0|10|9|7
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
0.56
0.56
0.60
0.59
19.13%
17.37%
30.84%
15.60%
Revenuekr M
249.4
249.4
255.7
261.3
1.47%
3.08%
4.06%
6.35%
Peers (US$406.0M)
Cap (US$)
PE
156.3M
8.576x
407.0M
—
Capital
TTM
5Y
10Y
Leveragex
1.551
0.032
0.033
EBIT/Intx
0.625
1.859
1.910
Own earn%
0.18
7.69
7.15
Sh yield%
34.69
41.35
43.20
Owners
Insiders/Inst%
0.79
74.23
Short interest%
4.19
SBC / revenue%
2.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
8–12
$1 testx
0.1
Incr. ROIC%
10